Tuesday, 6 March, 2018 - 00:10
Phylogica lab success may have far reaching consequences
ASX-listed biotech Phylogica has achieved a medical milestone on its journey to developing a biological organism that is capable of carrying or “transporting” cancer fighting and other drugs directly inside the nucleus of a diseased cell. The Perth biotech said in a market update that it had successfully delivered a new “proof of concept cargo” known as “Cre” into kidney cells in the laboratory.